TITLE

The Effects of Chronic Treatment with OctreotideversusOctreotide plus Midodrine on Systemic Hemodynamics and Renal Hemodynamics and Function in Nonazotemic Cirrhotic Patients with Ascites

AUTHOR(S)
Kalambokis, Georgios; Economou, Michalis; Fotopoulos, Andreas; Al Bokharhii, Jihad; Pappas, Christos; Katsaraki, Afroditi; Tsianos, Epameinondas V.
PUB. DATE
April 2005
SOURCE
American Journal of Gastroenterology;Apr2005, Vol. 100 Issue 4, p879
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVES: The adrenergic agonist midodrine improved circulatory and renal dysfunction when acutely administered in nonazotemic cirrhotic patients with ascites while its combination with octreotide has recently been proposed as an effective treatment of type 1 hepatorenal syndrome (HRS). However, the effects of octreotide on systemic hemodynamics and renal function in cirrhotic patients are controversial. This study evaluated the effects of chronic treatment with octreotideversusoctreotide plus midodrine on systemic hemodynamics and renal hemodynamics, and function in nonazotemic cirrhotic patients with ascites.METHODS: Twenty-five patients were studied at baseline and 11 days after administration of subcutaneous octreotide 300μg, b.i.d. alone (n= 12) or together with oral midodrine 7.5 mg, t.i.d. (n= 13).RESULTS: Octreotide did not improve systemic hemodynamics whereas the addition of midodrine significantly decreased cardiac index (CI) and heart rate (HR), and increased mean arterial pressure (MAP) and systemic vascular resistance (SVR). Octreotide caused a decrease in renal vascular resistance (RVR) and increased renal blood flow (RBF) but significantly reduced glomerular filtration rate. The association of midodrine to octreotide did not modify renal hemodynamics and function as compared to baseline while it caused an almost significant minor increase in RVR and a significant minor decrease in RBF as compared to octreotide alone. Consequently, a significant minor increase in glomerular filtration rate was demonstrated. The plasma values of active renin, aldosterone, and glucagon were significantly reduced in either group.CONCLUSIONS: Octreotide does not improve systemic hemodynamics in nonazotemic cirrhotic patients with ascites while it impairs renal function. On the other hand, the addition of midodrine can ameliorate the hyperdynamic circulation without inducing renal dysfunction in these patients.(Am J Gastroenterol 2005;100:879–885)
ACCESSION #
16433595

 

Related Articles

  • Urinary NAG as a Biomarker of AKI in Patients with Hepatorenal Syndrome. Hassan, Ehab; Amir, Maher Al; Khaled, Yomna; Rawi, Hoda El; Roshdy, Nagwa // Journal of Applied Sciences Research;Sep2011, Vol. 7 Issue 9, p711 

    Early detection of acute kidney injury in patients with decompensated liver cirrhosis by urinary N-acetyl-b-D glucosaminidase (NAG). Background: Renal failure is a challenging complication of liver cirrhosis primarily related to reduction in systemic vascular resistance due to splanchnic...

  • New trends in hepatorenal syndrome. Coratelli, Pasquale; Passavanti, Giuseppe; Munno, Irene; Fumarola, Donato; Amerio, Alberta // Kidney International Supplement;Dec1985, Issue 17, pS143 

    Presents a study evaluating the incidence of systemic endotoxemia in a series of cirrhotic patients. Assessment of the possible pathogenetic role of endotoxins in hepatorenal syndrome; Detection of the transfer of lipid A across the dialysis membrane; Correlation between systemic endotoxemia in...

  • Afferent mechanisms of sodium retention in cirrhosis and hepatorenal syndrome. Oliver, Juan A.; Verna, Elizabeth C. // Kidney International;Apr2010, Vol. 77 Issue 8, p669 

    Cirrhosis induces extra-cellular fluid volume expansion, which when the disease is advanced can be severe and poorly responsive to therapy. Prevention and/or effective therapy for cirrhotic edema requires understanding the stimulus that initiates and maintains sodium retention. Despite much...

  • A 3-Month Course of Long-Acting Repeatable Octreotide (Sandostatin LAR) Improves Portal Hypertension in Patients With Cirrhosis: A Randomized Controlled Study. Spahr, Laurent; Giostra, Emiliano; Frossard, Jean-Louis; Morard, Isabelle; Mentha, Gilles; Hadengue, Antoine // American Journal of Gastroenterology;Jul2007, Vol. 102 Issue 7, p1397 

    OBJECTIVE: In patients with cirrhosis, acute octreotide administration may transiently decrease the hepatic venous pressure gradient (HVPG). Information on long-term effects of octreotide is limited and controversial. We evaluated portal and systemic hemodynamics following a prolonged...

  • The kidney in cirrhosis with portal hypertension. Olteanu, Dan; Lupu, Diana // Journal of Medicine & Life;Apr-Jun2010, Vol. 3 Issue 2, p175 

    Ascites, dilutional hyponatremia and hepatorenal syndrome are three clinical manifestations of the same physiopathological disorder: cirrhotic portal hypertension, hyperproduction of nitric oxide, arterial vasodilation with reduction of efficient arterial volume, which have as consequences renal...

  • Hepatorenal syndrome: the 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group.  // Critical Care;2012, Vol. 16 Issue 1, pR23 

    The article presents a diagnostic criteria for the hepatorenal syndrome (HRS). HRS is a unique form of kidney injury resulting from renal vasoconstriction in the setting of systemic and splanchnic arterial vasodilatation in patients with advanced cirrhosis. HRS is subdivided into two types:...

  • DIAGNOSIS, PREVENTION AND TREATMENT OF HEPATORENAL SYNDROME IN CIRRHOSIS. Salerno, Francesco; Gerbes, Alexander; Ginès, Pere; Wong, Florence; Arroyo, Vicente // Gut;Sep2007, Vol. 56 Issue 9, p1310 

    Hepatorenal syndrome (HRS) is a serious complication of end-stage liver disease, occurring mainly in patients with advanced cirrhosis and ascites, who have marked circulatory dysfunction, as well as in patients with acute liver failure. In spite of its functional nature, HRS is associated with a...

  • Zaburzenia mikroflory jelitowej w marskoÅ›ci wÄ…troby - potencjalne implikacje kliniczne i terapeutyczne. Marlicz, Wojciech; Raszeja-Wyszomirska, Joanna; Ławniczak, Małgorzata; Milkiewicz, Piotr // Gastroenterologia Polska / Gastroenterology;2008, Vol. 15 Issue 3, p195 

    The imbalance of intestinal microflora in patients with liver cirrhosis is common and plays an important role in the pathogenesis of life threatening complications. Hepatorenal syndrome is an example of serious complication of decompensated cirrhosis. It occurs as a consequence of several...

  • Pitfalls in assessing renal function in patients with cirrhosis—potential inequity for access to treatment of hepatorenal failure and liver transplantation. Davenport, Andrew; Cholongitas, Evangelos; Xirouchakis, Elias; Burroughs, Andrew Kenneth // Nephrology Dialysis Transplantation;Sep2011, Vol. 26 Issue 9, p2735 

    Serum creatinine is universally used to assess renal function in clinical practice. Creatinine and changes in serum creatinine are used to define acute kidney injury and hepatorenal syndrome (HRS) in patients with progressive liver disease. In addition, creatinine is a key variable in the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics